Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer

E. Hessmann, M. S. Patzak, L. Klein, N. Chen, V. Kari, I. Ramu, T. E. Bapiro, K. K. Frese, A. Gopinathan, F. M. Richards, D. I. Jodrell, C. Verbeke, X. Li, R. Heuchel, J. M. Löhr, S. A. Johnsen, T. M. Gress, V. Ellenrieder, A. Neesse

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


Objective Desmoplasia and hypovascularity are thought to impede drug delivery in pancreatic ductal adenocarcinoma (PDAC). However, stromal depletion approaches have failed to show clinical responses in patients. Here, we aimed to revisit the role of the tumour microenvironment as a physical barrier for gemcitabine delivery. Design Gemcitabine metabolites were analysed in LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) murine tumours and matched liver metastases, primary tumour cell lines, cancer-associated fibroblasts (CAFs) and pancreatic stellate cells (PSCs) by liquid chromatography-mass spectrometry/mass spectrometry. Functional and preclinical experiments, as well as expression analysis of stromal markers and gemcitabine metabolism pathways were performed in murine and human specimen to investigate the preclinical implications and the mechanism of gemcitabine accumulation. Results Gemcitabine accumulation was significantly enhanced in fibroblast-rich tumours compared with liver metastases and normal liver. In vitro, significantly increased concentrations of activated 2′,2′-difluorodeoxycytidine-5′-triphosphate (dFdCTP) and greatly reduced amounts of the inactive gemcitabine metabolite 2′,2′-difluorodeoxyuridine were detected in PSCs and CAFs. Mechanistically, key metabolic enzymes involved in gemcitabine inactivation such as hydrolytic cytosolic 5′-nucleotidases (Nt5c1A, Nt5c3) were expressed at low levels in CAFs in vitro and in vivo, and recombinant expression of Nt5c1A resulted in decreased intracellular dFdCTP concentrations in vitro. Moreover, gemcitabine treatment in KPC mice reduced the number of liver metastases by >50%. Conclusions Our findings suggest that fibroblast drug scavenging may contribute to the clinical failure of gemcitabine in desmoplastic PDAC. Metabolic targeting of CAFs may thus be a promising strategy to enhance the antiproliferative effects of gemcitabine.

Original languageEnglish (US)
Pages (from-to)497-507
Number of pages11
Issue number3
StatePublished - Mar 2018



ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer'. Together they form a unique fingerprint.

Cite this